Updated listing of late-stage industry-sponsored cell therapy trials.

We've just updated our listing of industry-sponsored pivotal, ph3 and 2/3 cell therapy trials.  See the posting here.

Late-stage industry-sponsored cell therapy trials

Tweet 

Updated 22 August 2012 (originally posted December 2011)

At Cell Therapy Group, we track cell therapy industry activity globally but  particularly activity related to the clinical development and commercialization of cell based therapeutic products globally.

Below is a synopsis of the pivotal, phase 3 or 2/3 industry-sponsored cell therapy trials we are currently tracking globally.  

There is a database behind this that includes more data fields like therapeutic category, cell/tissue source, cell type, expansion, indication, expected completion date, clinical trial site locations, etc. 

Industry-sponsored pivotal, phase 3 or 2/3 trials*
    *active or expected to be active in 2012 

Aastrom                         

• Ixmyelocel-T

Argos

• Arcelis - AGS-003

Avita Medical

• ReCell

Baxter                           

• ACT34-CMI

Bone Therapeutics           

• PROEB

Cardio3 Biosciences         

• C-CURE

Cell Medica                     

• adoptive cellular therapy

CellCoTec

• INSTRUCT

CellSeed France               

• CAOMECS (Cultured Autologous Oral Mucosal Epithelial Cell-Sheet)

co.don                            

• co.don chondrosphere

Cook Myosite                  

• AMDC

Cytori                            

• ADRCs

DePuy Mitek

• CAIS

ERYtech Pharma              

• GRASPA

GamidaCell - Teva           

• StemEx

Harvest Technologies       

• SmartPReP 2 BMAC

Healthpoint                     

• HP802-247

Histogenics                     

• NeoCart

Innocell

• Immunecell-LC

Innovacell                        

• IES13 (Urocell?)

ISTO Technologies            

• DeNovo ET

JW Creagene

• CreaVax-RCC

Kiaidis Pharma                

• ATIR

MacroCure                       

• CureXcell

Mesoblast

• Revascor    

Miltenyi                          

• CliniMACS CD34 Selection System

MolMed                          

• TK

Newlink Genetics             

• HyperAcute Pancreas

NKBio

• Biocell Natural Killer Mixture

Northwest Biotherapeutics

• DCVax-L

NovaRx                          

• Lucanix

NuVasive                        

• Osteocel Plus

Osiris                            

• Prochymal

Pharmicell

• Heartcellgram-AMI

Prima Biomed                  

• Cvac

Sanofi (Genzyme)

• MACI

SOTIO

• DVAC/Pca

Tigenix (Cellerix)

• Cx601

The Hawkins Foundation (in collaboration with Depuy Mitek

• CAIS

TissueTec

• amniotic membrane

Some of the products listed above are in more than one clinical trial - different regions and/or different indications.

In total we are tracking 48 industry sponsored, active (or expected to be active 2012) cell therapy trials in pivotal, ph III or II/III expected to involve over 11,000 patients.  Some of the products listed above are the subject of multiple trials.

The 50 trials are sponsored by 40 companies.  The trials roughly break down as follows:

• 59% are autologous
• 45% are allogeneic
• Two are gene-modified allogeneic
• One involves autologous and allogeneic cells (we counted it for both)

• 30% for oncology or related indications
• 13% for cardiac-related indications
• 13% for non-cardiovascular (PAD, CLI, VLU, etc)  & wound 
• 34% (6) for cartilage and bone repair

___________________________________

I encourage readers to comment below or email direct with any errors and/or omissions.